RT Journal Article
SR Electronic
T1 Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
JF RMD Open
JO RMD Open
FD EULAR
SP e002508
DO 10.1136/rmdopen-2022-002508
VO 8
IS 2
A1 Yeoh, Su-Ann
A1 Gianfrancesco, Milena
A1 Lawson-Tovey, Saskia
A1 Hyrich, Kimme L
A1 Strangfeld, Anja
A1 Gossec, Laure
A1 Carmona, Loreto
A1 Mateus, Elsa F
A1 Schäfer, Martin
A1 Richez, Christophe
A1 Hachulla, Eric
A1 Holmqvist, Marie
A1 Scirè, Carlo Alberto
A1 Lorenz, Hanns-Martin
A1 Voll, Reinhard E
A1 Hasseli, Rebecca
A1 Jayatilleke, Arundathi
A1 Hsu, Tiffany Y-T
A1 D’Silva, Kristin M
A1 Pimentel-Quiroz, Victor R
A1 Vasquez del Mercado, Monica
A1 Shinjo, Samuel Katsuyuki
A1 Neto, Edgard Torres dos Reis
A1 Junior, Laurindo Ferreira da Rocha
A1 de Oliveira e Silva Montandon, Ana Carolina
A1 Pons-Estel, Guillermo J
A1 Ornella, Sofía
A1 D'Angelo Exeni, Maria Eugenia
A1 Velozo, Edson
A1 Jordan, Paula
A1 Sirotich, Emily
A1 Hausmann, Jonathan S
A1 Liew, Jean W
A1 Jacobsohn, Lindsay
A1 Gore-Massy, Monique
A1 Sufka, Paul
A1 Grainger, Rebecca
A1 Bhana, Suleman
A1 Wallace, Zachary
A1 Robinson, Philip C
A1 Yazdany, Jinoos
A1 Machado, Pedro M
A1 ,
YR 2022
UL http://rmdopen.bmj.com/content/8/2/e002508.abstract
AB Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65–1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51–0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.Data are available on reasonable request. Applications to access the data should be made to the COVID-19 Global Rheumatology Alliance Steering Committee.